Status:
TERMINATED
Primary Percutaneous Pericardiotomy for Malignant Pericardial Effusion (PMAP)
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Pericardial Effusion Malignant
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Pericardial effusion is a common complication in patients with metastatic malignancy. While pericardiocentesis provide effective relieve from life-threatening situation such as cardiac tamponade, recu...
Detailed Description
Pericardial effusion is a common complication in patients with metastatic malignancy with an incidence as high as 21%. The occurrence of malignant pericardial effusion significantly impacts on patient...
Eligibility Criteria
Inclusion
- Patients with confirmed active malignancy AND,
- Presence of at least moderate (\>10cm) pericardial effusion on CT or Echocardiography
Exclusion
- Patients unable to give an informed consent,
- Previous history of open-heart surgery
- Previous history of pericardial window or pericardial instillation of sclerosing therapy.
- Scheduled thoracic or cardiac surgery within the next 3 months
- Patients with contraindications for endovascular procedure such as disseminated intravascular coagulopathy or significant ongoing bleeding tendency, and systemic septicaemia.
- Patient with small or loculated pericardial effusion that is not accessible by subxiphoid approach.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04472468
Start Date
January 1 2020
End Date
September 30 2024
Last Update
November 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Hong Kong, Shatin, Hong Kong, 0000